ntreated IIIB/IV period with the EGFR mutation in the gene, phase II study of Gefitinib and the pemetrexed / bevacizumab combination maintenance therapy after Gefitinib and the cisplatin / pemetrexed / bevacizumab combination induction therapy for non-squamous epithelium non-small cell lung cancer of the latter recurrence

Phase 2

Recruiting

• Conditions: non-squamous non-small cell lung cancer

• Registration Number: JPRN-UMIN000016550
• Lead Sponsor: International University of Health and Welfare Respiratory Disease Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-02-16
• Study Completion: 2018-05-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 27

Inclusion Criteria

Not provided

Exclusion Criteria

1) The case that a squamous cancer ingredient accounts for more than 50% in the case of mixed type with the squamous cancer. 2) A mixed case with small cell lung cancer. 3) We have EGFR resistance gene mutation (T790M). 4) With the symptom or metastases to brain case to need treatment such as a steroid or the antispasmodic. 5) The case with a history of the hemoptysis or the merger. 6) The case with a history, the merger of the following sputum bloody.d 7) A case that was given the radiotherapy for the chest. 8) It is a case of after the palliative irradiation for bone metastases or the metastases to brain except the primary tumor for less than two weeks. 9) The invasion of the primary tumor is found in in great vessels in trachea or lobar bronchus or the TNM classification T4 of the lung cancer handling agreement revision seventh edition partly. 10) A case with the superior vena caval syndrome. 11) A case with the interstitial pneumonia that is clear by chest CT or pulmonary fibrosis. 12) The case with a serious infection. 13) The case with serious complications. 14) The case with pleural effusion, ascitic fluid requiring treatment such as the drainage and the pericardial fluid. 15)A case with the multiple primary cancer of the activity. 16)A case with a history of serious drug allergy. 17)Uncontrollable hypertension < 160/100 18) A case with a history of less than one year before merger of cerebrovascular disorder with the symptom or registration. 19) Need to antiplatelet therapy or anticoagulation therapy without Aspirin 325 mg/day 20) Gastrointestinal perforation within 1 year 21) The case that it was judged mental disorder to become the clinical problem to have difficulty in registration to this study. 22) With pregnancy and the pregnant likelihood or women nursing or men in hope of fertility. 23)Inappropriate for this study judged by the attending physician

Study & Design

• Study Type: Interventional
• Study Design: Not specified